Data from EMC - Curated by Toby Galbraith - Last updated 11 July 2017
EMA (European Medicines Agency)
DuoResp Spiromax is indicated in adults 18 years of age and older only.
DuoResp Spiromax is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:
-in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.
-in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.
Symptomatic treatment of patients with severe COPD (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
View highlights from recent congresses presented in new expert videos with leading physicians.
+ 3 more
- To evaluate the efficacy of dupilumab (SAR231893 / REGN668) in patients with persistent asthma.
Added 4 days ago
dose-finding study to assess the optimal dose of glycopyrrolate daily dose on top of BDP/FF in COPD patients.
Added 5 days ago
Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease
Efficacy of Fixed Combination of The purpose of this study is to determine the triple combination of beclometasone dipropionate+Formoterol fumarate+Glycopyrrolate bromide is effective for the treatment of severe COPD
Added 5 days ago
A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
The primary objective of this study is to determine whether reslizumab, at a dosage of 0.3 or 3.0 mg/kg administered once every 4 weeks for a total of 4 doses, is more effective than placebo in improving lung function ...
Added 3 months ago
The primary objective of this study is to determine whether reslizumab is more effective than placebo in reducing the number of clinical asthma exacerbations (CAEs) in patients with eosinophilic asthma.
Added 3 months ago
Treating tobacco dependence: guidance for primary care on life-saving interventions. Position statement of the IPCRG.
Tobacco smoking is the world's leading cause of premature death and disability. Global targets to reduce premature deaths by 25% by 2025 will require a substantial increase in the number of smokers making a quit attempt...
Added 1 month ago
The impact of asthma, chronic bronchitis and allergic rhinitis on all-cause hospitalizations and limitations in daily activities: a population-based observational study.
Chronic respiratory diseases are a significant cause of morbidity and mortality worldwide. We sought to evaluate the impact of asthma, chronic bronchitis and allergic rhinitis on all-cause hospitalizations...
Added 4 months ago
Keys to successful management of patients with allergic rhinitis: Focus on patient confidence, compliance and satisfaction.
The American Academy of Otolaryngic Allergy (AAOA) convened an expert, multidisciplinary Working Group on Allergic Rhinitis to discuss patients' self-treatment behaviors and how health care providers approach and treat the condition.
Added 5 months ago
The present guideline (S2k) on allergen-specific immunotherapy (AIT) was established by the German, Austrian and Swiss professional associations for allergy in consensus with the scientific specialist societies and professional associations...
Added 6 months ago
Inert gas washout tests, performed using the single- or multiple-breath washout technique, were first described over 60 years ago. As...
Added 5 years ago
|Agency product number||EMEA/H/C/002348|
|Date First Approved||28-04-2014|
|Type||Medicinal product subject to medical prescription|
|Marketing authorisation holder||Teva Pharma B.V.|